Beacon developing saliva-based cancer tests under agreement with Centocor.
This article was originally published in The Gray Sheet
Executive Summary
BEACON DIAGNOSTICS SALIVA-BASED GASTROINTESTINAL CANCER TEST 510(k) is slated for submission to FDA in early 1998, the company says. The GI kit is the first product expected to come to market under an exclusive worldwide licensing agreement between Beacon and Centocor covering tumor detection technology.